Cartesian Therapeutics stockholders elect three Class III directors and approve say-on-pay at 2025 annual meeting

Cartesian Therapeutics, Inc.

84.31% of outstanding shares represented; each director nominee elected with votes for >19.2M.
Non-binding advisory say-on-pay approved: 19.7M for, 157k against, 2.0M broker non-votes.
Ratification of Ernst & Young as independent auditor for FY2025 approved: 21.8M for, 6k against.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.